The U.S. accounted for the highest share of over 70% in the global ulcerative colitis therapeutics market due to rise in prevalence of ulcerative colitis, presence of key players, and rise in access to healthcare due to well-established healthcare infrastructure.

Chicago, Aug. 09, 2022 (GLOBE NEWSWIRE) -- According to Arizton’s latest research report, ulcerative colitis market is expected to grow a at CAGR of 8.7% during 2022-2027. With more than 150+ molecules in various stages of development, it is expected that new vendors are likely to enter the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating ulcerative colitis.

Ulcerative Colitis Market Report Scope

Click Here to Download the Free Sample Report

The Ulcerative colitis report provides a detailed analysis of the drugs available for the treatment of Ulcerative colitis. The report covers a detailed drug description including drug name, sponsor name, route of administration, molecule type, mechanism of action of the drug, clinical studies, NDA approvals, Ulcerative colitis (Ulcerative colitis) collaborations, licensing, mergers and acquisition, designations, and other product-related details.

Presently, the Ulcerative colitis market comprises of patented drugs as well as off-label drugs. Off-label drugs used in treatment of Ulcerative colitis includes 5-aminosalicyclic acid(5-ASA) including mesalamine, olsalazine and sulfasalazine; corticosteroids including Prednisone, Prednisolone & Methy prednisol; Immunosuppressants including Azathioprine, 6-Mercaptopurine, Cyclosporine & Tacrolimus. The US is expected to account for a significant share of the global Ulcerative colitis treatment market during the forecast period.

Market Drivers

• The Ulcerative colitis mortality rate is higher in developing countries, due to improper detection at early stages of the disease.

• Increased incidence of Ulcerative colitis cases will increase expensive long-term prescriptions.

• Adoption of advanced technologies in ulcerative colitis treatment and rise in the number of treatments will boost the Ulcerative colitis treatment market
  

Key Insights

• The U.S. accounted for the highest share of over 70% in the global ulcerative colitis therapeutics market due to rise in prevalence of ulcerative colitis, presence of key players, and rise in access to healthcare due to well-established healthcare infrastructure.

• TNF-alpha inhibitors are accounted for significant share of over 69% in the global ulcerative colitis therapeutics due to its wide recommendation in front line setting. However, the other class of drugs are expected to fastest growing segment during the forecast period.

• Men were accounted for a significant share of 52.74% in the global ulcerative colitis therapeutics. This is due to men are more likely affected than women.

• Total colitis is accounted for a significant share of 42.7% in the global ulcerative colitis therapeutics market. However, Proctitis is expected to fastest growing segment during the forecast period.

• The prominent players in ulcerative colitis therapeutics market includes Abbvie, Janssen Pharmaceuticals, Takeda, Pfizer, Bristol-Myers-Squibb, Gilead Bioscience, and many others.

• The promising late-stage drugs with various mechanism of action including integrin and adhesion blockers, sphingosine-1-phosphate (S1P) receptor modulators, interleukin inhibitors, TNF-alpha inhibitors and others are expected to enter the market in near future.

Key Vendors

• Johnson & Johnson

• AbbVie Inc (AbbVie)

• Takeda Pharmaceutical Co Ltd (Takeda)

• Pfizer Inc (Pfizer)

• Bristol-Myers Squibb

• EA Pharma

• Eli Lilly and Company

• InDex

• Reistone Biopharma Co. Ltd.

• CellTrion

Market Segmentation
Drug Class

• TNF-Alpha inhibitors

• 5-Aminosalicylates

• Corticosteroids & Others
  

Gender Type

• Men

• Women

Disease Type

• Total Colitis

• Left-sided Colitis & Proctitis

Geography

• North America

  • US

• Europe

  • France

  • Germany

  • Italy

  • UK

  • Spain

• APAC

  • China

  • Japan
    

Explore our  healthcare lifesciences profile to know more about the industry.

Click Here to Download the Free Sample Report

Read some of the top-selling reports:

• Cervical Cancer Therapeutics Market - Epidemiology & Pipeline Analysis 2022-2027

• Anti-Inflammatory Drugs Market - Global Outlook & Forecast 2022-2027

• Graft Versus Host Disease (GvHD) Treatment Market Forecast – Epidemiology & Pipeline Analysis 2022-2027

• Immunotherapy Drugs Market - Global Outlook & Forecast 2021-2026

About Arizton:

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals, and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Click Here to Contact Us

Call: +1-312-235-2040  
+1 302 469 0707  

CONTACT: Arizton Advisory and Intelligence Call: +1-312-235-2040  +1 302 469 0707